Menu

Report Library

All Reports

Q2 2015 Outlook Report

April 07, 2015

In this quarter's report, we cover catalysts from 24 drugs, devices and diagnostics. We have also included a list of Large Impact catalysts in the drug, device/diagnostic, and natural resource areas through Q2 2015 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Early 2015 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 67% of catalyst outcomes that occurred in early 2015.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Acute Myelogenous Leukemia (AML)
Aortic Aneurysm
Asthma
Bipolar Disorder
Bladder Cancer
Breast Cancer
Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Chronic Idiopathic Constipation
Diabetes Mellitus, Type II
Dyslipidemia / Hypercholesterolemia
Hepatitis C (HCV) (Antiviral)
Interstitial Cystitis / Painful Bladder Syndrome
Melanoma
Multiple Myeloma (MM)
Non-Small Cell Lung Cancer (NSCLC)
Pancreatic Cancer
Prostate Cancer
Renal Cell Cancer (RCC)
Rheumatoid Arthritis (RA)
Schizophrenia
Skin and Skin-Structure Infections (Antibacterial)
X-Linked Hypophosphatemia (XLH)

 Additional Resources: